Anthrax toxin antagonist - PharmAtheneAlternative Names: DNI Therapeutic - PharmAthene; Dominant negative inhibitor - PharmAthene; Therapeutic anthrax antitoxin - PharmAthene; ToxBlox
Latest Information Update: 20 May 2008
At a glance
- Originator PharmAthene
- Mechanism of Action Anthrax toxin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 20 May 2008 Discontinued - Preclinical for Anthrax in USA (IV)
- 03 Apr 2006 No development reported - Preclinical for Anthrax in USA (IV)
- 31 Mar 2004 Preclinical trials in Anthrax in USA (IV)